Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682158 · ClinicalTrials.gov registry record · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
A Phase 2 study of Esophageal Adenocarcinoma, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT04682158 is a Phase 2 study of Esophageal Adenocarcinoma that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 106 participants, below the 306-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04682158, a Phase 2 study of Esophageal Adenocarcinoma, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT, or definitive chemotherapy or chemotherapy-immunotherapy and will be considered separately as a single arm prospective cohort
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Propranolol
- RADIATION 3 Dimensional Conformal Radiation Therapy
- RADIATION Intensity Modulated Radiation Therapy
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2029-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04682158
The ClinicalTrials.gov registry entry for NCT04682158 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 306-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (65% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04682158 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04682158 about?
NCT04682158 is a clinical study titled "Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma". This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT, or defin...
What is the current status of trial NCT04682158?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2021-04-01. Estimated completion is 2029-04-01.
What conditions does trial NCT04682158 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT04682158?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Propranolol (DRUG), 3 Dimensional Conformal Radiation Therapy (RADIATION), Intensity Modulated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04682158?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04682158 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
RECRUITING · Phase 2
-
Obeticholic Acid for Prevention in Barrett's Esophagus
RECRUITING · Phase 2
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.